



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/00	A2	(11) International Publication Number: WO 99/58559 (43) International Publication Date: 18 November 1999 (18.11.99)
(21) International Application Number: PCT/US99/10793 (22) International Filing Date: 14 May 1999 (14.05.99) (30) Priority Data: 09/081,385 14 May 1998 (14.05.98) US (71) Applicant (for all designated States except US): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 12th floor, 1111 Franklin Street, Oakland, CA 94607-5200 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): GATANAGA, Tetsuya [JP/US]; 77 Wellesley, Irvine, CA 92612 (US). GRANGER, Gale, A. [US/US]; 31562 Santa Rosa, Laguna Beach, CA 92651 (US). (74) Agents: CAMPBELL, Cathryn et al.; Campbell and Flores, Suite 700, 4370 La Jolla Village Drive, San Diego, CA 92122 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: FACTORS AFFECTING TUMOR NECROSIS FACTOR RECEPTOR RELEASING ENZYME ACTIVITY (57) Abstract The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are method for identifying additional compounds that influence TNF receptor shedding. As the active ingredient in a pharmaceutical composition, the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathology of disease.		